Concepedia

Author

Sam Jackson

Dynavax Technologies (United States)

Also Known As

S. Jackson, Sam J. Jackson, Sam Jackson, Simone B. Jackson

31

Publications

643

Citations

10

H-Index

9

Concepts

All Affiliations

Dynavax Technologies (United States)AstraZeneca (Sweden)Stanford University
SJ

About

Sam Jackson is an author at Dynavax Technologies (United States) specializing in vaccinology, vaccination, and humoral immunity.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

1

1

44

2

Immunology

1

1

44

3

Humoral Immunity

1

1

44

4

Viral Hepatitis

1

1

44

5

Hepatitis

1

1

44

Sam Jackson

×

8

Publications

484

Citations

8

H-Index

YearCitations

Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults

Sam Jackson, Joseph R. Lentino, James Kopp,

Vaccine

2017

185

Safety, Tolerability, and Feasibility of Young Plasma Infusion in the Plasma for Alzheimer Symptom Amelioration Study

Sharon J. Sha, Gayle K. Deutsch, Lü Tian,

JAMA Neurology

2018

108

Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults

Randall N. Hyer, Darren K. McGuire, Biao Xing,

Vaccine

2018

58

Immunogenicity of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in subpopulations of healthy adults 18–70 years of age

Julia M. Janssen, Sam Jackson, William L. Heyward,

Vaccine

2015

44

First‐in‐Human Study With the Inhaled TLR9 Oligonucleotide Agonist AZD1419 Results in Interferon Responses in the Lung, and Is Safe and Well‐Tolerated

Sam Jackson, Albert F. Candia, Stephen Delaney,

Clinical Pharmacology & Therapeutics

2017

29

A Phase 2a, Double-Blind, Placebo-controlled Randomized Trial of Inhaled TLR9 Agonist AZD1419 in Asthma

Ioannis Psallidas, Vibeke Backer, Piotr Kuna,

American Journal of Respiratory and Critical Care Medicine

2020

26

Progression in multiple sclerosis is associated with low endogenous <scp>NCAM</scp>

Sharmilee Gnanapavan, Peggy P. Ho, Wendy Heywood,

Journal of Neurochemistry

2013

19

Safety and tolerability of GRF6019 in mild‐to‐moderate Alzheimer's disease dementia

Jonas Hannestad, Katie Koborsi, Vicki Klutzaritz,

Alzheimer s & Dementia Translational Research & Clinical Interventions

2020

15

Page 1